pioglitazone has been researched along with Lung Neoplasms in 23 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone is a PPARγ agonist commonly prescribed for the clinical treatment of diabetes." | 5.46 | Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice. ( Antonides, JD; Galbraith, AR; Haynes, AM; Miller, KA; Miller, WA; O'Sullivan, MG; Ondrey, FG; Seabloom, DE; Steele, VE; Suen, CS; Wuertz, BR, 2017) |
| " However, emerging data suggest that chronic use of these agents is associated with increased risk of adverse cardiovascular events." | 2.44 | Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors. ( Nemenoff, RA, 2007) |
| "Pioglitazone treatment significantly reduced squamous lesions and the presence of airway basal cells, along with increasing normal epithelial cells in the airways of NTCU-exposed mice." | 1.72 | PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model. ( Alavi, K; Dwyer-Nield, LD; Ghosh, M; Hudish, LI; Hudish, TM; Keith, RL; McArthur, DG; Merrick, DT; Mirita, C; Smith, AJ; Sompel, K; Tennis, MA, 2022) |
| " This study aimed to investigate the anti-cancer potential of PPAR-γ agonist Pioglitazone combined with COX-2 inhibitor Celelcoxib in NSCLC." | 1.72 | Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer. ( Kiran, AVVVR; Krishnamurthy, PT; Kumari, GK, 2022) |
| "Using a mouse model of lung squamous cell carcinoma (SCC), we performed transcriptome sequencing (RNA-Seq) to profile bronchial airway gene expression and found activation of the PI3K and Myc signaling networks in cytologically normal bronchial airway epithelial cells of mice with preneopastic lung SCC lesions, which was reversed by treatment with the PI3K Inhibitor XL-147 and pioglitazone, respectively." | 1.46 | Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents. ( Lubet, RA; Miller, MS; Pan, J; Szabo, E; Wang, Y; Xiong, D; You, M; Zhang, Q, 2017) |
| "Pioglitazone is a PPARγ agonist commonly prescribed for the clinical treatment of diabetes." | 1.46 | Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice. ( Antonides, JD; Galbraith, AR; Haynes, AM; Miller, KA; Miller, WA; O'Sullivan, MG; Ondrey, FG; Seabloom, DE; Steele, VE; Suen, CS; Wuertz, BR, 2017) |
| "Treatment with metformin alone and in combination with pioglitazone resulted in statistically significant decreases in lung adenoma formation at both early- and late-stage interventions." | 1.46 | Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention. ( Antonides, JD; Clapper, ML; Galbraith, AR; Haynes, AM; Miller, KA; Miller, MS; Miller, WA; O'Sullivan, MG; Ondrey, FG; Seabloom, DE; Steele, VE; Wuertz, BR, 2017) |
| "small vs." | 1.38 | Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. ( Behrens, C; Bookout, AL; Gadzar, AF; Girard, L; Jeong, Y; Lee, W; Mangelsdorf, DJ; Minna, JD; Raso, G; Wistuba, II; Xie, Y, 2012) |
| "Pioglitazone was introduced by oral gavage." | 1.37 | Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice. ( Chen, DR; Chen, R; Fu, H; Lu, Y; Lubet, RA; Pan, J; Szabo, E; Wang, Y; Wen, W; You, M; Zhang, J; Zhang, Q, 2011) |
| "When pioglitazone was administered beginning 8 weeks after the first carcinogen treatment when microscopic adenomas already existed, pioglitazone significantly inhibited tumor load (sum of tumor volume per lung in average) by 64% (P < 0." | 1.36 | Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. ( James, M; Lu, Y; Lubet, RA; Szabo, E; Wang, Y; Wen, W; You, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Dwyer-Nield, LD | 2 |
| McArthur, DG | 1 |
| Hudish, TM | 1 |
| Hudish, LI | 1 |
| Mirita, C | 1 |
| Sompel, K | 1 |
| Smith, AJ | 1 |
| Alavi, K | 1 |
| Ghosh, M | 1 |
| Merrick, DT | 2 |
| Tennis, MA | 1 |
| Keith, RL | 2 |
| Zhou, J | 1 |
| Liu, Z | 1 |
| Zhang, L | 1 |
| Hu, X | 1 |
| Wang, Z | 1 |
| Ni, H | 1 |
| Wang, Y | 4 |
| Qin, J | 1 |
| Kiran, AVVVR | 1 |
| Kumari, GK | 1 |
| Krishnamurthy, PT | 1 |
| Tseng, CH | 1 |
| Blatchford, PJ | 1 |
| Bunn, PA | 1 |
| Bagwell, B | 1 |
| Jackson, MK | 1 |
| Geraci, MW | 1 |
| Miller, YE | 1 |
| Liclican, EL | 1 |
| Walser, TC | 1 |
| Hazra, S | 1 |
| Krysan, K | 1 |
| Park, SJ | 1 |
| Pagano, PC | 1 |
| Gardner, BK | 1 |
| Larsen, JE | 1 |
| Minna, JD | 2 |
| Dubinett, SM | 1 |
| Xiong, D | 1 |
| Pan, J | 2 |
| Zhang, Q | 2 |
| Szabo, E | 3 |
| Miller, MS | 2 |
| Lubet, RA | 3 |
| You, M | 3 |
| Seabloom, DE | 2 |
| Galbraith, AR | 2 |
| Haynes, AM | 2 |
| Antonides, JD | 2 |
| Wuertz, BR | 2 |
| Miller, WA | 2 |
| Miller, KA | 2 |
| Steele, VE | 2 |
| Suen, CS | 1 |
| O'Sullivan, MG | 2 |
| Ondrey, FG | 2 |
| Clapper, ML | 1 |
| Reddy, RC | 2 |
| Srirangam, A | 1 |
| Reddy, K | 1 |
| Chen, J | 1 |
| Gangireddy, S | 1 |
| Kalemkerian, GP | 1 |
| Standiford, TJ | 2 |
| Keshamouni, VG | 2 |
| Kusakabe, M | 1 |
| Watanabe, K | 1 |
| Emoto, N | 1 |
| Aki, N | 1 |
| Kage, H | 1 |
| Nagase, T | 1 |
| Nakajima, J | 1 |
| Yatomi, Y | 1 |
| Ohishi, N | 1 |
| Takai, D | 1 |
| Li, MY | 2 |
| Yuan, H | 2 |
| Ma, LT | 2 |
| Kong, AW | 2 |
| Hsin, MK | 2 |
| Yip, JH | 1 |
| Underwood, MJ | 2 |
| Chen, GG | 2 |
| James, M | 1 |
| Wen, W | 2 |
| Lu, Y | 2 |
| Fu, H | 1 |
| Zhang, J | 1 |
| Chen, R | 1 |
| Chen, DR | 1 |
| Li, H | 1 |
| Sorenson, AL | 1 |
| Poczobutt, J | 1 |
| Amin, J | 1 |
| Joyal, T | 1 |
| Sullivan, T | 1 |
| Crossno, JT | 1 |
| Weiser-Evans, MC | 1 |
| Nemenoff, RA | 2 |
| Wan, IY | 1 |
| Yoo, JY | 1 |
| Yang, SH | 1 |
| Lee, JE | 1 |
| Cho, DG | 1 |
| Kim, HK | 1 |
| Kim, SH | 1 |
| Kim, IS | 1 |
| Hong, JT | 1 |
| Sung, JH | 1 |
| Son, BC | 1 |
| Lee, SW | 1 |
| Jeong, Y | 1 |
| Xie, Y | 1 |
| Lee, W | 1 |
| Bookout, AL | 1 |
| Girard, L | 1 |
| Raso, G | 1 |
| Behrens, C | 1 |
| Wistuba, II | 1 |
| Gadzar, AF | 1 |
| Mangelsdorf, DJ | 1 |
| Arenberg, DA | 1 |
| Newstead, MJ | 1 |
| Anthwal, S | 1 |
| Ihle, NT | 1 |
| Paine-Murrieta, G | 1 |
| Berggren, MI | 1 |
| Baker, A | 1 |
| Tate, WR | 1 |
| Wipf, P | 1 |
| Abraham, RT | 1 |
| Kirkpatrick, DL | 1 |
| Powis, G | 1 |
| Costa, DB | 1 |
| Huberman, MS | 1 |
| Mori, A | 1 |
| Sakurai, H | 1 |
| Choo, MK | 1 |
| Obi, R | 1 |
| Koizumi, K | 1 |
| Yoshida, C | 1 |
| Shimada, Y | 1 |
| Saiki, I | 1 |
1 review available for pioglitazone and Lung Neoplasms
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors.
Topics: Animals; Antineoplastic Agents; Humans; Lung Neoplasms; Pioglitazone; PPAR gamma; Rosiglitazone; Sig | 2007 |
1 trial available for pioglitazone and Lung Neoplasms
| Article | Year |
|---|---|
A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers.
Topics: Aged; Biopsy; Bronchopulmonary Dysplasia; Bronchoscopy; Carcinoma in Situ; Chemoprevention; Double-B | 2019 |
21 other studies available for pioglitazone and Lung Neoplasms
| Article | Year |
|---|---|
PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Desmoglein 3; Epithelial-Mesenchy | 2022 |
Activation of β2-Adrenergic Receptor Promotes Growth and Angiogenesis in Breast Cancer by Down-regulating PPARγ.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemic Agents; Lung | 2020 |
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung | 2022 |
Pioglitazone and lung cancer risk in Taiwanese patients with type 2 diabetes.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Piogli | 2018 |
Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.
Topics: Bronchi; Cell Line; Cell Proliferation; Chemokine CXCL1; Enzyme-Linked Immunosorbent Assay; Epitheli | 2014 |
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Topics: Animals; Biomarkers, Tumor; Bronchi; Carcinoma, Squamous Cell; Chemokines, CXC; Chemoprevention; Dis | 2017 |
Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.
Topics: Adenoma; Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents; Chemoprevention; Dose | 2017 |
Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Dose-Response Rel | 2017 |
Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromans; Gene Exp | 2008 |
Impact of DNA demethylation of the G0S2 gene on the transcription of G0S2 in squamous lung cancer cell lines with or without nuclear receptor agonists.
Topics: Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; DNA M | 2009 |
Roles of peroxisome proliferator-activated receptor-alpha and -gamma in the development of non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gene Expression Regulation, Ne | 2010 |
Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinogens; Carcinoma, Squamous Cell; Chemopreventi | 2010 |
Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzo(a)pyrene; Budesonide; Carcinogens; Ce | 2011 |
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.
Topics: Adenocarcinoma; Animals; Bone Marrow; Coculture Techniques; Disease Progression; Fluorescent Antibod | 2011 |
Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Transformati | 2012 |
E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model.
Topics: Aged; Animals; Brain; Brain Neoplasms; Cadherins; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Li | 2012 |
Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma | 2012 |
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer.
Topics: Amino Acid Motifs; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Ce | 2005 |
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme In | 2005 |
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gl | 2006 |
Severe pulmonary metastasis in obese and diabetic mice.
Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Hypoglycemic Agents; Killer Cells, Natural; Leptin | 2006 |